Patents Assigned to Selecta Biosciences, Inc.
  • METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
    Publication number: 20240350462
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: December 1, 2023
    Publication date: October 24, 2024
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
    Publication number: 20240261396
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class Il-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: August 29, 2023
    Publication date: August 8, 2024
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS
    Publication number: 20240156955
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Application
    Filed: June 6, 2023
    Publication date: May 16, 2024
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
  • SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND ANTI-IGM AGENTS
    Publication number: 20230372535
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist, an anti-IgM agent and immunosuppressant (e.g., synthetic nanocarriers comprising immunosuppressant) in combination. The methods and compositions provided can be used for modulating an immune response to an antigen, such as by enhancing regulatory T cells, such as antigen-specific regulatory T cells.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 23, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
    Publication number: 20230364124
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Application
    Filed: March 17, 2023
    Publication date: November 16, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
    Publication number: 20230321224
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.
    Type: Application
    Filed: December 8, 2022
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
    Publication number: 20230321225
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: March 2, 2023
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers for allergy therapy
    Patent number: 11779641
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 10, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
    Publication number: 20230310593
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 5, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers
    Patent number: 11717569
    Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: August 8, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
  • OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS
    Publication number: 20230139671
    Abstract: This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.
    Type: Application
    Filed: July 28, 2022
    Publication date: May 4, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset
  • Methods and compositions for attenuating anti-viral transfer vector immune responses
    Patent number: 11633422
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: April 25, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
    Publication number: 20230119226
    Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 20, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Lloyd Johnston
  • METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
    Publication number: 20230107561
    Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
    Type: Application
    Filed: August 30, 2022
    Publication date: April 6, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Lloyd Johnston
  • METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY
    Publication number: 20230032226
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: March 9, 2022
    Publication date: February 2, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS FOR PROVIDING POLYMERIC SYNTHETIC NANOCARRIERS FOR GENERATING ANTIGEN-SPECIFIC TOLERANCE IMMUNE RESPONSES
    Publication number: 20220354947
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Application
    Filed: December 16, 2021
    Publication date: November 10, 2022
    Applicant: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE
    Publication number: 20220323607
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including antigen-specific regulatory T cells.
    Type: Application
    Filed: April 8, 2022
    Publication date: October 13, 2022
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
    Patent number: 11426451
    Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.
    Type: Grant
    Filed: March 11, 2018
    Date of Patent: August 30, 2022
    Assignee: Selecta Biosciences, Inc.
    Inventor: Lloyd Johnston
  • Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
    Patent number: 11298342
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: April 12, 2022
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
    Publication number: 20220071968
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: March 24, 2021
    Publication date: March 10, 2022
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto